Journal article
Ebola virus glycoprotein stimulates IL-18–dependent natural killer cell responses
- Abstract:
-
Background NK cells are activated by innate cytokines and viral ligands to kill virus-infected cells. These functions are enhanced during secondary immune responses and after vaccination by synergy with effector T cells and virus-specific antibodies. In human Ebola virus infection, clinical outcome is strongly associated with the initial innate cytokine response, but the role of NK cells has not been thoroughly examined.
Methods The novel 2-dose heterologous Adenovirus type 26.ZEBOV (Ad26.ZEBOV) and modified vaccinia Ankara-BN-Filo (MVA-BN-Filo) vaccine regimen is safe and provides specific immunity against Ebola glycoprotein, and is currently in phase 2 and 3 studies. Here, we analyzed NK cell phenotype and function in response to Ad26.ZEBOV, MVA-BN-Filo vaccination regimen and in response to in vitro Ebola glycoprotein stimulation of PBMCs isolated before and after vaccination.
Results We show enhanced NK cell proliferation and activation after vaccination compared with baseline. Ebola glycoprotein–induced activation of NK cells was dependent on accessory cells and TLR-4–dependent innate cytokine secretion (predominantly from CD14+ monocytes) and enriched within less differentiated NK cell subsets. Optimal NK cell responses were dependent on IL-18 and IL-12, whereas IFN-γ secretion was restricted by high concentrations of IL-10.
Conclusion This study demonstrates the induction of NK cell effector functions early after Ad26.ZEBOV, MVA-BN-Filo vaccination and provides a mechanism for the activation and regulation of NK cells by Ebola glycoprotein.
Trial registration ClinicalTrials.gov NCT02313077.
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Not applicable (or unknown), 799.3KB, Terms of use)
-
(Preview, Version of record, 2.6MB, Terms of use)
-
- Publisher copy:
- 10.1172/jci132438
Authors
- Publisher:
- American Society for Clinical Investigation
- Journal:
- Journal of Clinical Investigation More from this journal
- Volume:
- 130
- Issue:
- 7
- Pages:
- 3936-3946
- Place of publication:
- United States
- Publication date:
- 2020-04-21
- Acceptance date:
- 2020-04-16
- DOI:
- EISSN:
-
1558-8238
- ISSN:
-
0021-9738
- Pmid:
-
32315287
- Language:
-
English
- Keywords:
- Pubs id:
-
1100974
- Local pid:
-
pubs:1100974
- Deposit date:
-
2020-05-03
Terms of use
- Copyright holder:
- Wagstaffe et al.
- Copyright date:
- 2020
- Rights statement:
- © 2020 Wagstaffe et al. This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
- Licence:
- CC Attribution (CC BY)
If you are the owner of this record, you can report an update to it here: Report update to this record